Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, Dean PT, Opalenik SR, Schreeder DM, Rimm DL, Kim JY, Bordeaux J, Loi S, Horn L, Sanders ME, Ferrell PB Jr, Xu Y, Sosman JA, Davis RS, Balko JM.

JCI Insight. 2018 Dec 20;3(24). pii: 120360. doi: 10.1172/jci.insight.120360.

2.

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.

Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, Sanders ME, Cook RS, Arteaga CL, Johnson DB, Balko JM.

Oncoimmunology. 2018 Mar 6;7(6):e1438106. doi: 10.1080/2162402X.2018.1438106. eCollection 2018.

3.

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.

Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL.

Sci Transl Med. 2016 Apr 13;8(334):334ra53. doi: 10.1126/scitranslmed.aad3001. Erratum in: Sci Transl Med. 2019 Jan 23;11(476):.

4.

Supplemental Content

Support Center